Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).

Saved in:
Bibliographic Details
Title: Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).
Authors: Li, Grace1 (AUTHOR) g.li@nhs.net, Marchevsky, Natalie G.1 (AUTHOR), Macaulay, Grace1 (AUTHOR), Aley, Parvinder1 (AUTHOR), Baughan, Hannah1 (AUTHOR), Plested, Emma1 (AUTHOR), Bibi, Sagida1 (AUTHOR), Cappuccini, Federica1 (AUTHOR), Faust, Saul N.2 (AUTHOR), Heath, Paul T.3 (AUTHOR), Muller, Jill1 (AUTHOR), Robinson, Hannah1 (AUTHOR), Roderick, Marion4 (AUTHOR), Snape, Matthew1 (AUTHOR), Smith, David1 (AUTHOR), Song, Rinn1 (AUTHOR), Liu, Xinxue1 (AUTHOR), Lambe, Teresa1,5 (AUTHOR), Pollard, Andrew J.1,6 (AUTHOR)
Source: Vaccine. Aug2025, Vol. 62, pN.PAG-N.PAG. 1p.
Database: Environment Complete
Description
ISSN:0264410X
DOI:10.1016/j.vaccine.2025.127597